RT Journal Article
T1 Contemporary management of patients undergoing atrial fibrillation ablation: in-hospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation ablation long-term registry
A1 Arbelo, Elena
A1 Brugada, Josep
A1 Blomstrom-Lundqvist, Carina
A1 Laroche, Cecile
A1 Kautzner, Josef
A1 Pokushalov, Evgeny
A1 Raatikainen, Pekka
A1 Efremidis, Michael
A1 Hindricks, Gerhard
A1 Barrera, Alberto
A1 Maggioni, Aldo
A1 Tavazzi, Luigi
A1 Dagres, Nikolaos
A1 ESC-EHRA Atrial Fibrillation, 
K1 Atrial fibrillation
K1 Ablation
K1 Prospective registry
K1 Management
K1 Outcomes
K1 Complications
K1 Eurobservational research-program
K1 Catheter ablation
K1 Radiofrequency ablation
K1 Multicenter
K1 Guidelines
AB Aims The ESC-EHRA Atrial Fibrillation Ablation Long-Term registry is a prospective, multinational study that aims at providing an accurate picture of contemporary real-world ablation for atrial fibrillation (AFib) and its outcome.Methods and results A total of 104 centres in 27 European countries participated and were asked to enrol 20-50 consecutive patients scheduled for first and re-do AFib ablation. Pre-procedural, procedural and 1-year follow-up data were captured on a web-based electronic case record form. Overall, 3630 patients were included, of which 3593 underwent an AFib ablation (98.9%). Median age was 59 years and 32.4% patients had lone atrial fibrillation. Pulmonary vein isolation was attempted in 98.8% of patients and achieved in 95-97%. AFib-related symptoms were present in 97%. Inhospital complications occurred in 7.8% and one patient died due to an atrioesophageal fistula. One-year follow-up was performed in 3180 (88.6%) at a median of 12.4 months (11.9-13.4) after ablation: 52.8% by clinical visit, 44.2% by telephone contact and 3.0% by contact with the general practitioner. At 12-months, the success rate with or without antiarrhythmic drugs (AADs) was 73.6%. A significant portion (46%) was still on AADs. Late complications included 14 additional deaths (4 cardiac, 4 vascular, 6 other causes) and 333 (10.7%) other complications.Conclusion AFib ablation in clinical practice is mostly performed in symptomatic, relatively young and otherwise healthy patients. Overall success rate is satisfactory, but complication rate remains considerable and a significant portion of patients remain on AADs. Monitoring after ablation shows wide variations. Antithrombotic treatment after ablation shows insufficient guideline-adherence.
PB Oxford univ press
SN 0195-668X
YR 2017
FD 2017-05-01
LK http://hdl.handle.net/10668/18947
UL http://hdl.handle.net/10668/18947
LA en
DS RISalud
RD Apr 6, 2025